Company intelligence / Profile preview

Opsis Therapeutics

Madison, Wisconsin, United States

Ownership: Private
Development stage: Other

Overview

Opsis Therapeutics, in partnership with BlueRock Therapeutics, is advancing OpCT-001, an iPSC-derived cell therapy for primary photoreceptor diseases, which has IND clearance, FDA Fast Track designation, and has begun Phase 1/2a clinical trial dosing; additional programs for dry AMD and inherited retinal diseases are at preclinical stages[1][5].

Therapeutic areas: Ophthalmology
Modalities: Induced pluripotent stem cell derived therapyCell therapy
Industry: Biotech

Partnerships

FUJIFILM Cellular DynamicsBlueRock Therapeutics

Beyond the preview

Go deeper on Opsis Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Opsis Therapeutics.

Explore the full profile